Emergent Biosolutions Inc. (NYSE:EBS) Stock Has Consensus Price Target of $10.00 According to Analysts

Key Points

• Analysts have a consensus “Hold” rating on Emergent BioSolutions, with two sells, one hold and three buys; the average 12-month price target is $10.00 versus the stock’s $7.21 opening price.
• Emergent reported quarterly earnings of $0.60 per share, beating the $0.08-per-share loss analysts expected, while revenue of $234.3 million exceeded the $177.5 million consensus estimate.
• Institutional investors own 78.4% of the company, with BlackRock, Ancora Advisors and Palisade Capital among recent buyers; a director separately sold 17,800 shares under a pre-arranged trading plan.

Shares of Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) have been assigned a consensus recommendation of "Hold" from the six ratings firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $10.00.

EBS has been the topic of several analyst reports. Zacks Research upgraded shares of Emergent Biosolutions to a "hold" rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. began coverage on Emergent Biosolutions in a research report on Friday, August 21st. They set an "underweight" rating for the company. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Emergent Biosolutions in a report on Wednesday, September 9th. Finally, Weiss Ratings upgraded Emergent Biosolutions from a "sell (d-)" rating to a "sell (d)" rating in a research report on Friday, August 21st.

Insider Transactions at Emergent Biosolutions

In other news, Director Donald Degolyer sold 17,800 shares of the stock in a transaction on Wednesday, October 7th. The stock was sold at an average price of $7.09, for a total value of $126,202.00. Following the completion of the transaction, the director owned 111,921 shares of the company's stock, valued at approximately $793,519.89. This represents a 13.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.00% of the company's stock.

Hedge Funds Weigh In On Emergent Biosolutions

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Emergent Biosolutions during the 2nd quarter worth about $39,525,000. Ancora Advisors LLC acquired a new stake in shares of Emergent Biosolutions in the 2nd quarter worth approximately $8,949,000. Palisade Capital Management LP bought a new position in shares of Emergent Biosolutions in the second quarter valued at approximately $4,316,000. Dimensional Fund Advisors LP boosted its holdings in shares of Emergent Biosolutions by 22.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,757,158 shares of the biopharmaceutical company's stock valued at $22,884,000 after acquiring an additional 504,553 shares in the last quarter. Finally, Pacer Advisors Inc. acquired a new position in shares of Emergent Biosolutions during the first quarter valued at approximately $3,454,000. Institutional investors own 78.40% of the company's stock.

Emergent Biosolutions Stock Up 1.6%

Emergent Biosolutions stock opened at $7.21 on Friday. The company has a 50-day simple moving average of $6.43 and a 200-day simple moving average of $8.08. The firm has a market capitalization of $369.40 million, a P/E ratio of -2.03 and a beta of 2.28. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.95 and a current ratio of 5.42. Emergent Biosolutions has a one year low of $4.36 and a one year high of $14.06.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.68. The business had revenue of $234.30 million for the quarter, compared to analysts' expectations of $177.50 million. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. As a group, equities analysts expect that Emergent Biosolutions will post 0.13 earnings per share for the current year.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company that develops, manufactures and supplies medical countermeasures for public health threats. Its portfolio has included products for protection against anthrax and smallpox, as well as treatments and emergency medicines used in overdose response and other acute-care settings.

The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology companies, supporting activities such as drug substance and product manufacturing, packaging and related commercialization services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.